Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lipocine (LPCN) Equity Average (2016 - 2025)

Lipocine's Equity Average history spans 13 years, with the latest figure at $15.6 million for Q3 2025.

  • For Q3 2025, Equity Average fell 22.45% year-over-year to $15.6 million; the TTM value through Sep 2025 reached $15.6 million, down 22.45%, while the annual FY2024 figure was $20.7 million, 26.14% down from the prior year.
  • Equity Average reached $15.6 million in Q3 2025 per LPCN's latest filing, down from $18.2 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $44.0 million in Q1 2022 to a low of $15.6 million in Q3 2025.
  • Average Equity Average over 5 years is $29.0 million, with a median of $28.9 million recorded in 2021.
  • Peak YoY movement for Equity Average: skyrocketed 349.61% in 2021, then tumbled 41.53% in 2023.
  • A 5-year view of Equity Average shows it stood at $39.2 million in 2021, then decreased by 6.5% to $36.6 million in 2022, then crashed by 41.53% to $21.4 million in 2023, then dropped by 6.39% to $20.1 million in 2024, then decreased by 22.05% to $15.6 million in 2025.
  • Per Business Quant, the three most recent readings for LPCN's Equity Average are $15.6 million (Q3 2025), $18.2 million (Q2 2025), and $20.1 million (Q1 2025).